At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 538 enrolled
Drug / intervention
meningococcal B rLP2086 vaccine. +3 morebiological
Likely dose
meningococcal B rLP2086 vaccine. 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years
In Brief
A Phase 2 clinical trial evaluating meningococcal B rLP2086 vaccine. and normal saline (placebo) for Meningitis, Meningococcal. Completed, enrolled 538 participants across 27 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity of an investigational meningococcal B rLP2086 vaccine in adolescents aged 11 to 18 years old.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningitis, Meningococcal
CountriesAustralia, Poland, Spain
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartFeb 2009
Primary CompletionMar 2014
TodayJul 2026
First PostedDec 15, 2008
Enrollment StartFeb 1, 2009
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 17.5 years ago
Interventions
meningococcal B rLP2086 vaccine.biological
vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
meningococcal B rLP2086 vaccine.biological
vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
meningococcal B rLP2086 vaccine.biological
vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
normal saline (placebo)other
vaccine, 0.5 mL, 0 - 2 - 6 to 9 months